Showing 4061-4070 of 7413 results for "".
- Syneron Medical Appoints William Griffing to Newly Created Position of CEO of Syneron Candela North Americahttps://practicaldermatology.com/news/syneron-medical-appoints-william-griffing-to-newly-created-position-of-ceo-of-syneron-candela-north-america/2459009/Syneron Medical Ltd. appointed William Griffing to the newly created position of Chief Executive Officer of Syneron Candela North America, effective immediately. In this position, Mr. Griffing will be responsible for aligning and managing the Company's growth strategies for its North American
- Mikael Svensson Named Sr. VP of Sales/Marketing for Revision Skincarehttps://practicaldermatology.com/news/mikael-svensson-named-sr-vp-of-salesmarketing-for-revision-skincare/2459010/Revision Skincare appointed Mikael Svensson to the position of Senior Vice President of Sales and Marketing. In this new role, Mr. Svensson will oversee all Sales and Marketing activities, which include the strategic direction and leadership of Revis
- Halozyme Appoints Jean-Pierre Bizzari, MD to Board Of Directorshttps://practicaldermatology.com/news/halozyme-appoints-jean-pierre-bizzari-md-to-board-of-directors/2459021/Halozyme Therapeutics, Inc. appointed of Jean-Pierre Bizzari, MD to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development. "I am delighted to welcome Jean-Pierre to our Board of Directors," said Dr. Helen Torley, President and Chief Executi
- FDA Approves First IL-17A antagonist Cosentyx (secukinumab) from Novartis for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-first-il-17a-antagonist-cosentyx-secukinumab-from-novartis-for-moderate-to-severe-plaque-psoriasis/2459019/The FDA approved Cosentyx™ (secukinumab) from Novartis for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Cosentyx is the first approved psoriasis medication to selectively bind to IL-17A and inhibit its intera
- Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-lynne-bulger-as-vice-president-medical-affairs/2459022/Cipher Pharmaceuticals Inc. appointed Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products. Ms. Bulger has 27 years of experience in drug development in the pharmaceuti
- Suneva Medical's Bellafill Approved to Treat Acne Scarshttps://practicaldermatology.com/news/suneva-medicals-bellafill-approved-to-treat-acne-scars/2459034/Suneva Medical, Inc.'s Bellafill® is now the only filler on the market approved for the treatment of acne scars. FDA granted approval for Bellafil
- Modernizing Medicine, Inc. Acquires Aesyntix Health, Inc.https://practicaldermatology.com/news/modernizing-medicine-inc-acquires-aesyntix-health-inc/2459037/Modermizing Medicine, Inc., creator of the Electronic Medical Assistant® (EMA™), completed an acquisition of Aesyntix Health, Inc. on
- FDA Grants Bristol-Myers Squibb's Opdivo Accelerated Approval for Melanomahttps://practicaldermatology.com/news/fda-grants-bristol-myers-squibbs-opdivo-accelerated-approval-for-melanoma/2459039/The FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilim
- Gary D. Monheit, MD Wins Top ASDS Honorhttps://practicaldermatology.com/news/gary-d-monheit-md-wins-top-asds-honor/2459040/Gary D. Monheit, MD is the “very honored” 2014 recipient of the American Society for Dermatologic Surgery's highest honor: the Samuel J. Stegman, MD, Award for D
- Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Studyhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-to-meet-with-fda-on-operational-aspects-of-pv-10-phase-3-melanoma-study/2459043/Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will be me